Market Place
Sourcing Support
Monthly information related to total number of voting rights
08 Aug 2023 //
GLOBENEWSWIRE
PHAXIAM Therapeutics announces a reverse share split of its shares
27 Jul 2023 //
GLOBENEWSWIRE
Phaxiam Therapeutics announces its new mnemonic code on Euronext & Nasdaq: PHXM
28 Jun 2023 //
GLOBENEWSWIRE
Erytech & Pherecydes Announce Merger And Name Change To Phaxiam Therapeutics
26 Jun 2023 //
GLOBENEWSWIRE
Meet Phaxiam: Erytech`s merger with Pherecydes is complete
26 Jun 2023 //
FIERCE BIOTECH
ERYTECH announces the approval of the merger with Pherecydes and reports
23 Jun 2023 //
GLOBENEWSWIRE
ERYTECH announces that Akkadian is continuing its attempt at destabilization
20 Jun 2023 //
GLOBENEWSWIRE
Erytech`s war with investor rumbles on as merger vote nears
13 Jun 2023 //
FIERCE BIOTECH
Monthly information related to total number of voting rights
13 Jun 2023 //
GLOBENEWSWIRE
ERYTECH Responds to Akkadian™s Disinformation
12 Jun 2023 //
GLOBENEWSWIRE
Activist investor aims to obstruct Erytech-Pherecydes merger
05 Jun 2023 //
FIERCE BIOTECH
ERYTECH Announces the Availability of the Documents for Annual General Meeting
24 May 2023 //
GLOBENEWSWIRE
ERYTECH announces availability of the exemption document relating to Pherecydes
23 May 2023 //
GLOBENEWSWIRE
Monthly information related to total number of voting rights & shares composing
16 May 2023 //
GLOBENEWSWIRE
ERYTECH Provides Update on the Announced Combination with PHERECYDES
15 May 2023 //
GLOBENEWSWIRE
Monthly information related to total number of voting rights
12 May 2023 //
GLOBENEWSWIRE
ERYTECH Provides Business and Financial Update for the First Quarter of 2023
09 May 2023 //
GLOBENEWSWIRE
ERYTECH Announces Approval to Transfer its Listing to the Nasdaq Capital Market
17 Apr 2023 //
GLOBENEWSWIRE
ERYTECH Provides Financial Update for the Fourth Quarter and Full Year 2022
22 Mar 2023 //
GLOBENEWSWIRE
Monthly information related to total number of voting rights and shares
06 Mar 2023 //
GLOBENEWSWIRE
Biotech consolidation continues as Erytech merges with phage therapy developer
16 Feb 2023 //
ENDPTS
By merging with Erytech, Pherecydes aims to boost AMR strategy
16 Feb 2023 //
FIERCE BIOTECH
Monthly information related to total number of voting rights _January 31, 2023
09 Feb 2023 //
GLOBENEWSWIRE
Monthly information related to total number of voting rights and shares
09 Jan 2023 //
GLOBENEWSWIRE
ERYTECH Provides Business and Financial Update for the Third Quarter of 2022
21 Nov 2022 //
GLOBENEWSWIRE
French penny stock will no longer knock on FDA door for approval
25 Aug 2022 //
ENDPTS
ERYTECH Provides Regulatory Update
24 Aug 2022 //
GLOBENEWSWIRE
Report : ERYTECH`s Combined Shareholders Meeting On June 24, 2022
24 Jun 2022 //
GLOBENEWSWIRE
ERYTECH Announces Availability of the Documents for its Annual General Meeting
24 May 2022 //
GLOBENEWSWIRE
ERYTECH to Present at the H.C. Wainwright Global Investment Conference
17 May 2022 //
GLOBENEWSWIRE
ERYTECH Provides Business and Financial Update for the First Quarter of 2022
12 May 2022 //
GLOBENEWSWIRE
Catalent Acquires Erytech`s Commercial-Scale Cell Therapy Mfg. Facility
25 Apr 2022 //
PRESS RELEASE
ERYTECH to Publish Positive Results from Eryaspase Phase 2 Trial in ALL
06 Apr 2022 //
GLOBENEWSWIRE
ERYTECH to Present Novel Vesiculation Approach at 24th Meeting of ERCS
04 Apr 2022 //
GLOBENEWSWIRE
ERYTECH to Participate in the Upcoming April Investor Conferences
28 Mar 2022 //
GLOBENEWSWIRE
ERYTECH Provides Business and Financial Update for Q4 and Full Year 2021
11 Mar 2022 //
GLOBENEWSWIRE
ERYTECH Expands Patent Portfolio for the Treatment of Rare Metabolic Diseases
08 Feb 2022 //
GLOBENEWSWIRE
ERYTECH to Present Results of Two Clinical Trials of Eryaspase at 2022 ASCO GI
24 Jan 2022 //
GLOBENEWSWIRE
ERYTECH Announces $7.85 Million Registered Direct Offering
14 Dec 2021 //
GLOBENEWSWIRE
ERYTECH Announces Presentation of Results of Expanded Access Program in ALL
13 Dec 2021 //
GLOBENEWSWIRE
ERYTECH Announces Upcoming Poster Presentation at the 2021 ASH
13 Nov 2021 //
GLOBENEWSWIRE
Erytech`s eryaspase flunks late-stage pancreatic cancer trial; shares drop
26 Oct 2021 //
MARKETWATCH
ERYTECH Announces Results from TRYbeCA-1 Phase 3 Trial of Eryaspase
23 Oct 2021 //
GLOBENEWSWIRE
ERYTECH Announces Maximum Tolerated Dose Declared in a Ph1 Investigator
04 Oct 2021 //
GLOBENEWSWIRE
ERYTECH Announces Maximum Tolerated Dose Declared in a Ph1 Investigator
04 Oct 2021 //
GLOBENEWSWIRE
ERYTECH Announces the Availability of its Half-Year Financial Report 2021
22 Sep 2021 //
GLOBENEWSWIRE
ERYTECH Provides Business Update and Reports Financial Results
20 Sep 2021 //
GLOBENEWSWIRE
ERYTECH to Host on September 21, 2021 Second Quarter 2021 conference call
16 Sep 2021 //
GLOBENEWSWIRE
ERYTECH Hosting Key Opinion Leader Webinar on Eryaspase in Pancreatic Cancer
24 Aug 2021 //
GLOBENEWSWIRE
ERYTECH Confirms Plans To Submit BLA for Hypersensitive ALL Patients
21 Jul 2021 //
GLOBENEWSWIRE
ERYTECH Requested a Pre-BLA Meeting with the FDA to Discuss Path to Approval
20 Apr 2021 //
GLOBENEWSWIRE
ERYTECH Announces Completion of First Cohort in a Ph 1 Investigator Trial
19 Apr 2021 //
GLOBENEWSWIRE
ERYTECH Provides Business Update and Reports Financial Results for the Year 2020
08 Mar 2021 //
GLOBENEWSWIRE
ERYTECH Announces First Patient Enrolled in a Phase 1 Investigator Sponsored
14 Jan 2021 //
GLOBENEWSWIRE
ERYTECH Completes Enrollment in TRYbeCA-1 Phase 3 Trial in Second-Line
14 Dec 2020 //
GLOBENEWSWIRE
ERYTECH Announces Positive Results from Eryaspase Phase 2 Trial
07 Dec 2020 //
GLOBENEWSWIRE
ERYTECH Announces Abstract with Results from Eryaspase Phase 2 Trial
04 Nov 2020 //
GLOBENEWSWIRE
ERYTECH Appoints Stewart Craig as Chief Technical Officer
26 Oct 2020 //
GLOBENEWSWIRE
ERYTECH establishes a financing facility with the implementation
21 Sep 2020 //
BIOSPACE
